Stock VIRO VIROGATES A/S
Add to a list
To use this feature you must be a member
Log inSign up

Other languages ViroGates A/S

Equities

VIRO

DK0061030574

Delayed Nasdaq Copenhagen
Other stock markets
 08:29:52 26/04/2024 pm IST 		5-day change 1st Jan Change
6.5 DKK -11.92% Intraday chart for ViroGates A/S +8.33% +7.97%
15/04 Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration CI
21/03 ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023
ViroGates A/S Provides Earnings Guidance for the Year 2024
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Virogates Provides Earnings Guidance for 2023
ViroGates A/S Announces an Agreement with Sobi for the Development of Suparnostic®
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2023
ViroGates A/S Announces the Commercial Launch of suPARnostic POC+ Product
ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms
ViroGates A/S Revises Earnings Guidance for Full-Year 2022 and 2023
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
ViroGates A/S Announces the Publication of A New Study That Shows SsuPAR upar Causes Cardiovascular Disease
ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023
ViroGates A/S Announces Board Changes
ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIRO Stock
  4. News ViroGates A/S
  5. Other languages